Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 22, 2021 09:25 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM

Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving...
September 12, 2019 16:20 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting

– TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial – – Presentations provide new estimate of global birth prevalence and highlight quality-of-life impact of...
May 30, 2019 16:02 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Reports First Quarter 2019 Financial Results

– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature endocrinology and...
January 07, 2019 09:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches

COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
December 12, 2016 08:29 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia

SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of...
October 19, 2016 17:01 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose Consistent Safety Profile at High Dose Findings Support 15...
April 20, 2016 10:36 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Provides Program Update on Vosoritide in Achondroplasia

New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocityfor up to 12 months with Increases of 46%-65% from Baseline Phase 3 Randomized Controlled Study Planned to Start at...